These values were similar to the values of other studies included in our analysis

These values were similar to the values of other studies included in our analysis. Results Anti-C1q antibodies discriminated between patients with and without a history BMP4 of LN, with a median specificity of 73.5%. The HSROC model estimated the corresponding sensitivity to be 70.4%. A hypothetical patient with a 55% prior probability of having a history of LN as opposed to no history (the median prevalence across 28 eligible studies) would have a post-test probability of 76.4% following a positive test result (positive predictive value) or 33.0% following a negative test result (negative predictive value). For discriminating active from inactive LN the median specificity of anti-C1q antibodies was 80%, with a corresponding estimated sensitivity value 75.7% based Gastrodin (Gastrodine) on the HSROC model. A hypothetical patient with a Gastrodin (Gastrodine) 56% prior probability of active as opposed to inactive LN (the median prevalence across the 9 eligible studies) would have a post-test probability of 82.8% following a positive test result or 27.9% following a negative test result. Conclusions Although C1q antibodies are associated with lupus nephritis the post-test probabilities are not sufficiently convincing to provide reasonable certainty of the presence or absence of history of disease/active disease. Keywords: Autoantibody, Biopsy, Diagnosis, Enzyme-linked immunosorbent assay (ELISA), Hierarchical summary receiver operating characteristic (HSROC), First component of match (C1q), Systemic lupus erythematosus (SLE) Introduction The first component of match C C1 is usually comprised of three subcomponents, C1q, C1s and C1r. The C1 complex plays a pivotal role in the activation of the classical pathway of match. Classical match activation has both inflammatory and anti-inflammatory functions. Intensive research in the 1970s afforded detailed information around the structure and function of C1q [1]. The C1q molecule is usually a 460 kDa glycoprotein with an exquisite tulip-like structure, consisting of six globular heads each composed from three polypeptide chains C A, B and C. Each head is usually attached to a central fibril region by a triple helical collagen like tail. The C1q component of C1 is usually synthesized in monocyte/macrophages and once secreted, can bind to aggregated antibody [2] primarily on microorganisms. This event triggers the activation of the classical match pathway that in turn amplifies the innate and adaptive immune responses against infectious brokers. C1q is usually a multi-functional protein [3], and binds to immune complexes deposited on tissues, including the kidney [4], and aids in their solubilization and removal [5]. C1q also plays a role in apoptotic cell debris removal [6]. Forty years ago, the possibility of antibodies against C1q in SLE patients was raised [7]. It was later proposed that binding of C1q to immune complexes led to conformational changes in the C1q structure exposing neoepitopes [8] that may invoke an immune response. Evidence for such a response, was exhibited by Uwatoko et al., who observed that IgG from SLE patient sera cross-reacted with C1q [9]. In later studies, we as well as others, suggested that post-translational modifications of C1q upon exposure to free radicals could generate antigenic neoepitopes [10-13] which could act as a trigger, leading to the breakdown of immune tolerance to C1q; this effect together with epitope distributing could then provoke the generation of antibodies to both post-translationally altered and unmodified forms of C1q (Physique 1). The binding of anti-C1q antibodies and other proteins to C1q is usually potentially of concern as it may impede the ability of C1q to carry out its normal anti-inflammatory functions such as, immune complex clearance and removal of apoptotic debris [14,15]. Open in a separate window Physique 1 Postulated sequence of events in the generation of anti-C1q antibodies that may act as diagnostic biomarkers of glomerulonephritis.Nucleosome blebs from apoptotic cells can deposit around the glomerular basement membrane (GBM) in SLE patients with LN and associate with a number of proteoglycan molecules. (A) During contamination Gastrodin (Gastrodine) and/or inflammation anti-bacterial polysaccharide or anti-dsDNA antibodies bind to host proteoglycans and nucleosomes, respectively. This prospects to the deposition of C1 (C1q/C1r2/C1s2) around the GBM and subsequent match activation. (B) The release of chemotactic peptides C5a and C3a triggers the recruitment of phagocytes to the GBM in close proximity to C1q. The activation of the phagocytes prospects to the release of free radicals that can post-translationally change (PTM) C1q. (C) The PTM-C1q can be taken up by antigen presenting cells, and the altered peptides offered to T-cells. The autoreactive T-cells in turn can trigger B-cell activation and ultimately the production of anti-C1q-producing.